Korro Bio, Inc.

NASDAQ:KRRO

Biotechnology

Healthcare
$12.44 +15.88%

+$1.76 today

Market cap
$170.75M
Beta
2.10
P/E (TTM)
-1.3
EPS (TTM)
-$9.79
52W Low $5.20High $55.89

Volume 0.16M

Average 0.15M

KRRO Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Korro Bio, Inc.NASDAQ: KRRO

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow turns negative

Q1 FY2026 investing cash flow was -$32.24M, compared with $32.78M a year earlier. Trailing-twelve-month investing cash flow was -$21.03M. Over 3 fiscal years it compounded at +58.4% a year.

Context

  • Investing cash flow amounted to 688.3% of revenue in FY2025, down 4743.1 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly investing cash flow holds near -$32.24M or moves back toward the trailing-twelve-month quarterly average of -$5.26M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$32.24M-316.1% QoQ
Last fiscal yearDec 2025
$43.99M+135.7% YoY
LTMMar 2026
-$21.03M-75.2% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-198.3%——
1 year+135.7%——
3-year CAGR+58.4%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
43.99M USD
Year-over-year change
+135.7%

Investing Cash Flow vs competitors

How KRRO compares with its peers on the latest reported figures

  • KRRO's LTM Mar 2026 investing cash flow of $21.03M is the 7th largest of the 11 companies compared; the peer median is $925K.
  • Its year-over-year change of -75.2% is the 6th highest of 9, against a peer median of -69.4%.
  • Investing cash flow amounts to 547.3% of revenue for KRRO, versus a peer median of 693.3%.
KRRO Competitors Peer median
Investing Cash Flow for KRRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALTAltimmune, Inc.LTM Mar 2026$131.06M -2272.1%+21.8%364061.1%
ANNXAnnexon, Inc.LTM Mar 2026$119.49M +372.3%+48.2%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$114.86M +4560.6%——
ENGNenGene Holdings Inc.LTM Apr 2026$60.78M -68.4%+447.7%—
AURAAura Biosciences, Inc.LTM Mar 2026$60.68M -32.0%——
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$42.41M ———
KRROKorro Bio, Inc.LTM Mar 2026$21.03M -75.2%+58.4%547.3%
AMRNAmarin Corporation plcLTM Mar 2026$11.72M -81.3%-63.0%5.5%
SLNSilence Therapeutics plcLTM Mar 2026$6.39M —+32.8%693.3%
DBVTDBV Technologies S.A.LTM Mar 2026$1.29M -229.4%+139.2%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$556K -70.3%-68.0%—
Peer median (excluding KRRO) $925K-69.4%+32.8%693.3%

Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.96M)(58.03M)(81.17M)(83.58M)(117.26M)
Depreciation & Amortization1.6M2.51M3.63M3.57M3.79M
Deferred Income Tax0(145K)000
Stock-Based Compensation807K1.14M2.38M4.46M7.66M
Change in Working Capital904K(633K)4.28M13.59M(4.43M)
Accounts Receivables000(1.7M)727K
Inventory00000
Accounts Payables56K1.76M3.1M(1.34M)(2.31M)
Other Working Capital848K(2.39M)1.18M16.63M(2.84M)
Other Non-Cash Items(13.44M)1.51M3.6M1.89M31.68M
Operating Cash Flow(32.09M)(53.65M)(67.28M)(60.07M)(78.56M)
Capital Expenditures(4.45M)(5.21M)(7.84M)(17.9M)(518K)
Acquisitions (Net)00000
Purchases of Investments(35.07M)(37.21M)0(146.35M)(26.19M)
Sales of Investments053.49M19M40.9M70.7M
Other Investing Activities13K0000
Investing Cash Flow(39.5M)11.06M11.16M(123.35M)43.99M
Debt Repayment00000
Common Stock Issued28K62K117.25M67.39M685K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2K)(44K)25.05M1.97M0
Financing Cash Flow115.95M18K187.76M69.36M685K
Effect of Forex Changes000(4K)64K
Net Change in Cash44.35M(42.57M)131.64M(114.07M)(33.82M)
Free Cash Flow(36.54M)(58.86M)(75.12M)(77.98M)(79.08M)

Korro Bio, Inc.

NASDAQ:KRRO

Intrinsic Alpha fair value

Locked

Current Price

$12.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.